Feed excerpt — reported by WHO
A full access package includes WHO policy guidance on the use of antigen-based rapid diagnostic tests, manufacturer volume guarantees for low and middle-income countries, catalytic funding to assist governments to deploy the tests and an initial US$50 million procurement fundSeveral rapid, point-of-care antigen tests are being assessed by WHO for Emergency Use Listing (EUL)Agreements between the Bill & Melinda Gates Foundation and test manufacturers Abbott and SD Biosensor make available innovative tests priced at a maximum of US$5 for low- and middle-income countries (LMICs)The Global Fund commits an initial US$50 million to enable countries to purchase the new tests, with…
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at WHO →